Ipamorelin

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively stimulates growth hormone release through the GHS receptor (GHS-R1a, also known as the ghrelin receptor). Developed in the 1990s, Ipamorelin demonstrates remarkable selectivity for GH release without significant effects on cortisol, prolactin, or ACTH secretion. Ipamorelin is utilized in laboratory research to study selective GH secretion, ghrelin receptor pharmacology, and growth hormone axis function. All discussion herein is limited to experimental research contexts and does not imply applied, therapeutic, or physiological use.

Ipamorelin is employed in laboratory research to study selective growth hormone secretion and GHS receptor pharmacology. Common experimental applications include GH secretion assays, pituitary function studies, and structure-activity relationship investigations. Research protocols utilize Ipamorelin to investigate the ghrelin/GHS-R1a signaling pathway, the selectivity determinants of GH secretagogues, and the advantages of targeted GH release without broad pituitary hormone stimulation.

Mechanistically, Ipamorelin activates GHS-R1a on pituitary somatotrophs, triggering Gq-protein coupling, phospholipase C activation, and intracellular calcium release. This calcium-dependent mechanism stimulates GH vesicle exocytosis and hormone release. Unlike less selective GH secretagogues, Ipamorelin does not activate ACTH-producing corticotrophs or prolactin-producing lactotrophs, resulting in GH release without cortisol or prolactin elevation. This selectivity enables cleaner GH axis research without confounding hormone changes.

Preclinical investigations of Ipamorelin include in-vitro receptor binding studies and in-vivo animal models evaluating GH secretion selectivity and dose-response relationships. Reported findings include robust, dose-dependent GH release with minimal effects on other pituitary hormones. Animal studies explore synergistic effects when combined with GHRH analogs, demonstrating amplified GH release exceeding either compound alone. All findings are interpreted strictly within the context of laboratory research models.